These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26273933)

  • 1. Developing an Anti-Xa-Based Anticoagulation Protocol for Patients with Percutaneous Ventricular Assist Devices.
    Sieg A; Mardis BA; Mardis CR; Huber MR; New JP; Meadows HB; Cook JL; Toole JM; Uber WE
    ASAIO J; 2015; 61(5):502-8. PubMed ID: 26273933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective anticoagulation for a percutaneous ventricular assist device using a heparin-based purge solution.
    Jennings DL; Nemerovski CW; Kalus JS
    Ann Pharmacother; 2013 Oct; 47(10):1364-7. PubMed ID: 24259702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
    Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
    Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An anticoagulation protocol for use after congenital cardiac surgery.
    Nair AG; Oladunjoye OO; Trenor CC; LaRonde M; van den Bosch SJ; Sleeper LA; VanderPluym C; Emani SM; Kheir JN
    J Thorac Cardiovasc Surg; 2018 Jul; 156(1):343-352.e4. PubMed ID: 29706371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study.
    Rizk E; Wilson AD; Murillo MU; Putney DR
    Ther Drug Monit; 2018 Feb; 40(1):151-155. PubMed ID: 29120972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of a Percutaneously Inserted Ventricular Support Device Purge Solution Heparin 25 U/mL.
    Jiang C; Stuart M; Makowski C; Jennings DL; To L
    Ann Pharmacother; 2021 Feb; 55(2):174-180. PubMed ID: 32741200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery.
    Oladunjoye OO; Sleeper LA; Nair AG; Trenor CC; VanderPluym C; Kheir JN; Emani SM
    J Thorac Cardiovasc Surg; 2018 Jul; 156(1):332-340.e1. PubMed ID: 29709361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation Management for Impella Percutaneous Ventricular Assist Devices: An Analysis of a Single-Center Experience.
    Wood E; Hayes C; Hart A
    Ann Pharmacother; 2020 Nov; 54(11):1073-1082. PubMed ID: 32410456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of protocol guided heparin anticoagulation in patients with the TandemHeart percutaneous ventricular assist device.
    Lee Y; Weeks PA
    ASAIO J; 2015; 61(2):207-8. PubMed ID: 25423119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
    Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
    Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of an argatroban-based purge solution in a percutaneous ventricular assist device.
    Laliberte B; Reed BN
    Am J Health Syst Pharm; 2017 May; 74(9):e163-e169. PubMed ID: 28438820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels.
    Schechter T; Finkelstein Y; Ali M; Kahr WH; Williams S; Chan AK; Deveber G; Brandão LR
    J Thromb Haemost; 2012 Mar; 10(3):368-74. PubMed ID: 22244010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
    Vandiver JW; Vondracek TG
    Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation.
    Sandner SE; Riebandt J; Haberl T; Mahr S; Rajek A; Schima H; Wieselthaler GM; Laufer G; Zimpfer D
    J Heart Lung Transplant; 2014 Jan; 33(1):88-93. PubMed ID: 24239003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.